PUBLISHER: The Business Research Company | PRODUCT CODE: 1942616
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942616
Contrast-enhanced ultrasound (CEUS) is a medical imaging technique that employs contrast agents or microbubbles to improve the visibility and clarity of ultrasound images. Its application extends to imaging blood perfusion in organs and measuring blood flow rates in the heart and other bodily organs.
The primary components of contrast-enhanced ultrasound are equipment and contrast agents. Equipment encompasses the physical tools, machinery, devices, or instruments designed to perform specific tasks, operations, or functions. This category includes ultrasound machines and associated devices utilized to generate real-time images using contrast agents. These technologies involve both non-targeted and targeted approaches, catering to the needs of hospitals, clinics, and various other applications.
Tariffs are influencing the contrast enhanced ultrasound market by increasing costs of imported ultrasound systems, imaging transducers, contrast agents, and electronic components. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported imaging equipment, while Asia-Pacific faces cost pressure on equipment manufacturing. These tariffs are raising capital and operating costs for imaging providers. However, they are also supporting domestic production, regional supplier partnerships, and development of cost-efficient ultrasound technologies.
The contrast enhanced ultrasound market research report is one of a series of new reports from The Business Research Company that provides contrast enhanced ultrasound market statistics, including contrast enhanced ultrasound industry global market size, regional shares, competitors with a contrast enhanced ultrasound market share, detailed contrast enhanced ultrasound market segments, market trends and opportunities, and any further data you may need to thrive in the contrast enhanced ultrasound industry. This contrast enhanced ultrasound market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The contrast enhanced ultrasound market size has grown strongly in recent years. It will grow from $2.13 billion in 2025 to $2.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to expansion of ultrasound imaging usage, increasing preference for radiation-free diagnostic methods, rising availability of contrast agents, growth in cardiovascular diagnostics, adoption of ultrasound in point-of-care settings.
The contrast enhanced ultrasound market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for real-time functional imaging, rising investments in advanced diagnostic ultrasound systems, expansion of ceus applications in oncology, growing focus on non-invasive imaging techniques, increasing approvals of next-generation contrast agents. Major trends in the forecast period include increasing adoption of microbubble-based imaging agents, rising use of ceus in cardiology and oncology, growing integration of advanced ultrasound software, expansion of portable contrast-enhanced ultrasound systems, enhanced focus on real-time perfusion imaging.
The rising prevalence of chronic diseases is expected to significantly drive the growth of the contrast-enhanced ultrasound market. Chronic diseases are long-term medical conditions that require ongoing management and care, and contrast-enhanced ultrasound (CEUS) provides real-time, detailed imaging crucial for diagnosing and monitoring these conditions. For instance, in September 2023, the World Health Organization reported that approximately 41 million deaths annually, accounting for 74% of all global deaths, are attributed to non-communicable diseases (NCDs), which include many chronic diseases like liver cirrhosis and vascular disorders linked to hypertension. CEUS is particularly valuable in these contexts, as it enhances the visibility of blood flow and tissue perfusion, aiding in the accurate assessment and management of chronic diseases. As the incidence of these conditions continues to rise, the demand for advanced imaging techniques such as contrast-enhanced ultrasound is likely to increase, further propelling market growth.
Major companies in the contrast-enhanced ultrasound market are focusing on developing advanced technologies, such as super-resolution contrast-enhanced ultrasound (CEUS) technology, to enhance spatial resolution. The integration of advanced technologies in contrast-enhanced ultrasound improves diagnostic capabilities, providing healthcare professionals with more detailed and accurate information about tissue and organ anatomy, function, and perfusion. In September 2023, Philips launched the Philips Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound (CEUS), utilizing advanced signal processing algorithms to enhance spatial resolution. This technology provides high-resolution images for diagnosing and treating various diseases, including cancer, liver disease, and vascular diseases.
In July 2024, GE HealthCare Technologies Inc., a US-based medical technology company, announced its acquisition of Intelligent Ultrasound Group PLC for an undisclosed amount. This strategic acquisition aims to integrate Intelligent Ultrasound's advanced solutions into GE HealthCare's existing ultrasound portfolio, enhancing both the efficiency and intelligence of their ultrasound offerings. The integration of these AI-driven technologies is expected to significantly improve the accuracy and usability of ultrasound systems, addressing the increasing demand for smarter imaging solutions within the healthcare industry. Intelligent Ultrasound Group PLC, based in the UK, specializes in innovative ultrasound systems, particularly focusing on applications related to contrast-enhanced ultrasound. This acquisition aligns with GE HealthCare's commitment to advancing imaging technologies and improving patient care through enhanced diagnostic capabilities.
Major companies operating in the contrast enhanced ultrasound market are General Electric Company, Bayer AG, Siemens Healthcare GmbH, Koninklijke Philips N.V., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Canon Medical Systems, Lantheus Medical Imaging Inc., Guerbet, Bracco Diagnostic Inc., Esaote S.p.A., Trivitron Healthcare Pvt. Ltd., BK Medical Holding Company Inc., Hitachi Healthcare, Chison Medical Technology Co. Ltd., SANOCHEMIA Pharmazeutika GmbH, SuperSonic Imagine SA, FUJIFILM Visualsonics Inc., Samsung Healthcare, Alpinion Medical Systems, Acusphere Inc., Solstice Pharmaceuticals B.V.
North America was the largest region in the contrast-enhanced ultrasound market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the contrast enhanced ultrasound market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the contrast enhanced ultrasound market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The contrast-enhanced ultrasound market consists of revenues earned by entities by providing services such as diagnostic imaging services, treatment planning services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The contrast-enhanced ultrasound market also includes sales of transducers, injectors, guidance tools, and imaging software that are used in providing comprehensive contrast-enhanced ultrasound. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Contrast Enhanced Ultrasound Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses contrast enhanced ultrasound market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for contrast enhanced ultrasound ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The contrast enhanced ultrasound market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.